Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
8-week placebo-controlled double-blind randomized fixed-dose trial of asenapine in adolescents with schizophrenia
2009-017971-10Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in schizophrenia comparing Asenapine fixed-dose with Placebo (2 arms). Primary endpoint: Change from baseline in PANSS total score at Day 56. Started Dec 2010; status: completed.
02
Drugs
asenapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2009-017971-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017971-10.